| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Nitric Oxide Monitoring Does Not Help Most Children With Asthma NEW YORK -- January 7, 2009 -- Calibrating medications based on daily monitoring of the fractional exhaled nitric oxide (FENO) and symptoms in asthmatic children showed no significant improvement over medicating based on daily symptom monitoring alone, according to a study published in the second issue for January of the American Journal of Respiratory and Critical Care Medicine. Johan C. de Jongste, MD, Erasmus University Medical Center-Sophia Children's Hospital, Erasmus, the Netherlands, and colleagues randomised 151 children from 15 academic centers and hospitals with mild to moderate asthma to a 30-week monitoring course. Families were called every 3 weeks and reported on the daily symptoms in the prior 3 weeks. The child's medication was adjusted accordingly. The researchers compared the rates of exacerbation, symptoms, use of medications, and other endpoints between the last 12 weeks in the 2 groups. There were no significant differences whether or not FENO had been part of the daily monitoring. However, both groups enjoyed an impressive overall improvement in symptoms, despite a reduction of about 50% in inhaled steroid dose, suggesting considerable benefit of frequent monitoring. "We speculate that daily supervision and frequent phone contacts have produced an improvement that could not be beaten by additional monitoring of FENO, most likely because of a ceiling effect on compliance," said Dr. de Jongste. The FENO group did, however, have nearly twice as many dosage changes as the symptom-only group, which supports the idea that the lack of difference may be a reflection on the limits of compliance, rather than an inherent limitation in the technique. Still, the added cost and apparent lack of benefit of daily FENO monitoring found in this study suggests that applying the technique in this way is not of benefit to the asthmatic population at large, when compared to daily symptom monitoring. Another possible explanation for the lack of improvement is that FENO monitoring is most likely to prompt a medication change that symptom-only monitoring would not suggest in patients whose symptoms and underlying inflammation are in discord, but the current study was not designed to assess these patients independently. Still, in light of these findings, it is clear that FENO monitoring should only be applied to those who stand to gain the most. "There can be no doubt that adding frequent assessments of FENO to management plans of most children and adults with asthma will add unjustifiable costs without providing clinical benefit. Whether there is a role for monitoring FENO to aid management of severe asthma is untested," said Stephen Stick, PhD, Princess Margaret Hospital for Children, Perth, Australia and Peter Franklin, PhD, Centre for Asthma, Allergy and Respiratory Research, University of Western Australia in Perth in an editorial that accompanied the article. SOURCE: American Thoracic Society
|